Madrigal reverse merges with Synta; newco to focus on cardio-metabolic diseases
- Intra-Biotech Deal
- Reverse Acquisition
- Payment Includes Stock
- Includes Contract
- Full Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.